Tag: SVY

Health Care

Latin American Contract Research Organizations Set to Get More Local Outsourcing Opportunities

admin

– Currently, multinational companies outsource a larger proportion of their clinical trials than local firms, finds Frost & Sullivan

SAO PAULO, April 7, 2015 /PRNewswire/ — As market penetration stood at only 64 percent in 2013, huge opportunities exist for contract research organizations (CROs) to expand their market share in Latin America (LATAM). Local contracts, which accounted for 21.6 percent of the total market size in 2013, will begin to contribute more to overall revenues. The local development of biosimilars, domestic pharmaceutical companies’ plans to increase the number of clinical trials to comply with regulations, and focus on geographic expansion will give rise to more local contracts for CROs in the region.

Research

Research

Photo – http://photos.prnewswire.com/prnh/20150407/196999

New analysis from Frost & Sullivan, Latin American Contract Research Organization Market (http://www.frost.com/p849), finds that the market earned revenues of $438.5 million in 2013 and estimates this to reach $661.3 million in 2019 at a compound annual growth rate of 7.1 percent. The study covers phase I, phase II, phase III and late phase clinical development as well as biostatistics, central laboratory services and data management. Health economics studies, a part of late phase trials, will gain significant traction in the coming years, since they are utilized while deciding which new molecules to include in the list of reimbursed drugs considered by public health services and private insurance plans.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/LA_PR_FValente_P849-52_27Mar15.

“Multinational pharmaceutical companies tend to outsource about 70 percent of their trials by adopting either a fully outsourced or function-to-function model,” said Frost & Sullivan Healthcare Consultant Sanjeev Kumar. “However, local pharmaceutical companies have lower outsourcing rates that range from 50 to 70 percent in countries across LATAM.”

In Argentina and Brazil, regulatory issues have restrained clinical development, thereby dampening the prospects of CROs in the region. Bottlenecks in the Agencia Nacional de Vigilancia Sanitaria (ANVISA) submission and approval processes have meant that protocol approval takes 12 to 15 months in Brazil and an average of 6 months in Argentina.

In addition, limited outsourcing among big pharmaceutical clients that can conduct in-house R&D and clinical drug testing has restricted CRO market growth. Nevertheless, as large, well-established CROs have begun to use specialized research technologies that can cater to the rising demand for drug development, pharmaceutical clients’ reliance on in-house R&D is likely to reduce considerably. Along with this trend, the rise of innovative therapeutic options as well as the need for increased drug efficacy and safety will promote market development.

“In order to better serve and become the preferred partner of bio-pharmaceutical companies, CROs in LATAM must make an effort to expand their range of services,” noted Kumar. “Mergers and acquisitions with local CROs will be a cost-effective approach to achieve this end.”

Latin American Contract Research Organization Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Global Diabetes Drug Delivery Market, Global CRO Market, Global Stem Cell Market, and Global Infectious Disease Diagnostics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Latin American Contract Research Organization Market
P849-52

Contact:
Francesca Valente
Corporate Communications – Latin America
P: +54 11 4777 5300
F: +54 11 4777 5300
E: francesca.valente@frost.com 

http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20150407/8521502174

Health Care

European Hospitals Will Move from Single-Use to Reusable Procedure Trays and Packs

admin

— The trend is catching on as hospitals try to make their operating rooms greener to reduce environmental impact, finds Frost & Sullivan

LONDON, April 7, 2015 /PRNewswire/ — Increasing procedure volumes have been fuelling the adoption of custom procedure trays and packs (CPTP) in Western and Eastern Europe. In part, the expanding aging population, which is more likely to develop chronic wounds as they have more medical issues affecting their general health and mobility, has been responsible for the growth in procedures and the resultant expansion of the CPTP market.

Frost & Sullivan

Frost & Sullivan

Logo – http://photos.prnewswire.com/prnh/20150407/196956LOGO

New analysis from Frost & Sullivan, Western and Eastern European Custom Procedure Trays and Packs (CPTP) Market, finds that the market earned revenues of $769.4 million in 2014 and estimates this to reach $1131.4 million in 2019. The study covers surgical and minor procedure trays and packs.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_MAC5-54_20Mar15

CPTP offer off-the-shelf convenience to hospitals, lower costs, and lead to more efficient operating rooms (ORs) with faster turnaround times between operations. Additionally, these products enable inventory reduction, easy storage, and simplified delivery schedules.

“In Western and Eastern Europe, single-use CPTP have particularly gained traction due to the stricter enforcement of infection-control measures within the hospital environment,” said Frost & Sullivan Healthcare Senior Research Analyst Parthasarathy Raghava. “For hospitals in these regions, these kits have been a natural choice as they ensure both compliance with safety standards and control over nosocomial and iatrogenic infections in the OR.”

However, with more hospitals involved in greening the OR, the future will see an emphasis on reusable and reprocessable kits rather than single-use or disposable kits. Thus, market participants that provide comprehensive CPTP services as well as reprocessing and serialization services will be in the best position to acquire new customers.

Nevertheless, certain challenges will continue to trouble market participants in Western and Eastern Europe. For one, the lack of standard regulations mandating the adoption of procedure packs will curtail usage rates in these regions. Furthermore, new entrants’ tendency to undercut prices to strengthen their foothold in the market will create pricing pressures and dampen overall market revenues.

“To remain competitive, market participants in Western and Eastern Europe will have to find a sweet spot between customizing trays and packs according to end-user preferences and standardizing these products to control costs,” noted Raghava. “Perhaps, standardizing only basic commodity items in packs is an appropriate starting point for CPTP providers to achieve these ends.”

Western and Eastern European Custom Procedure Trays and Packs (CPTP) Market is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: Western European Percutaneous Coronary Intervention (PCI) Devices Market, Western European Infant Care Solutions Market, Global Orthopaedic Implant Market, and Global Wound Care Market Outlook. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com 
http://www.frost.com 

Photo – http://photos.prnasia.com/prnh/20150407/8521502165

Health Care

Sentinel Studies Find New Microcurrent Generating Wound Dressing Effective in Disrupting Bacterial Biofilms

admin

TEMPE, Ariz., April 6, 2015 /PRNewswire/ — Procellera® from Vomaris Innovations, Inc. (now available through Arthrex as JumpStart™) – the only wound dressing powered by Advanced Microcurrent Technology™, has been found to significantly disrupt bacterial biofilms, according to two new published research studies in PLoS ONE and the Journal of Wound Care1-2.

Studies conducted at The Ohio State University (OSU) Wexner Medical Center, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and its Diagnostics and Translational Research Center (DTRC) both confirmed significant anti-biofilm efficacy of Procellera Technology. Bacterial biofilms are complex networks of microorganisms bound together and covered with a slimy protective barrier. They can be found in living tissues, indwelling medical devices, and implants. Biofilm-associated bacteria are extremely resistant to antibiotics and have been implicated in wound infections, resulting in delayed healing, poor clinical outcomes and significant healthcare costs.

In the OSU study, researchers evaluated the effects of Procellera / JumpStart technology to better understand its antimicrobial properties, particularly related to the disruption of Pseudomonas aeruginosa. This bacterial species is often present in chronic wound infections and readily forms biofilm, making it extremely difficult to treat effectively with available antibiotics.

“This work presents clear evidence that this wireless electroceutical dressing disrupts bacterial biofilm,” said Chandan K Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at OSU Wexner Medical Center. “Our findings introduce the option of a new affordable technology platform to fight chronic wound infection in which bacterial biofilms are abundant.”

Several mechanisms behind the ability of this Advanced Microcurrent Technology to disrupt the formation of bacterial biofilms were identified:

  • First, the microcurrent technology aided the generation of superoxide radicals, chemical compounds that are produced by white blood cells in the body with the goal to fight infection.
  • Second, researchers discovered that the microcurrents significantly impaired the activity of glycerol-3-phosphate dehydrogenase (GPDH), an electrically sensitive enzyme that is required for bacterial respiration and metabolism.
  • Finally, the research found that the microcurrents disrupted some key antimicrobial resistance genes, silenced some key redox-sensitive, quorum sensing genes and interfered with production of bacteria signaling molecules, thus preventing the bacteria from forming the complex networks that make up biofilms.

Because bacterial biofilms are known to compromise production of antimicrobial superoxide radicals by immune cells, weakening the ability of the body to fight infection, the study’s observation that Procellera initiated spontaneous generation of superoxide radicals is particularly significant.

Research performed at DTRC and HJF studied the anti-biofilm properties of Procellera Technology against ten clinical wound pathogens in a poloxamer biofilm model customized to evaluate the bioelectric dressing. Investigators demonstrated Procellera / JumpStart’s effectiveness against biofilms across multiple species of clinical wound pathogens, with up to a thousand-fold inhibition of microbial growth in several species when compared to controls. This observation is consistent with the observations reported independently from OSU.

“We are very encouraged by the implications of these results for wound care, which showed that this electroceutical dressing was effective in inhibiting growth of both mono- and multi-species biofilms, including multi-drug resistant strains,” said Dr. Mina Izadjoo, principal investigator for the DTRC/HJF study.

“Bacterial biofilms can dramatically impede wound healing and penetrate deeper into a wound bed to further infect implanted devices,” said Michael Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc. “Because of their resistance to treatment, biofilms present a significant challenge in today’s healthcare environment. We, at Vomaris, are extremely pleased by these latest findings by two independent laboratories about this Technology’s ability to inhibit and disrupt biofilms and the significant implications this has for infection control and wound healing.”

PLoS One study co-authors included Jaideep Banerjee, Piya Das Ghatak, Sashwati Roy, Ph.D., Savita Khanna, Ph.D., Craig Hemann, Jay L Zweier, M.D., and Daniel Wozniak, Ph.D. of The Ohio State University. The study was supported in part by the National Institutes of Health: Grant Numbers GM077185, GM069589 and DOD W81XWH-11-2-0142 to CKS; NIH NR013898 to CKS and DJW; and in part by NIH DK076566 to SR and NIH R01AI097511 to DJW.

Co-authors of the Journal of Wound Care article included Hosan Kim, Ph.D. The study was supported by Vomaris.

About Vomaris Innovations
Vomaris Innovations, Inc. is an electroceutical company specializing in microcurrent-generating solutions for the wound care market and beyond. Utilizing electricity to mimic the body’s own physiologic electric currents, which are essential for skin repair and wound healing, Vomaris’ core technology platform employs imbedded microcell batteries that generate microcurrents in the presence of a conductive medium to harness the power of electricity to support healing.

Vomaris’ flagship product, Procellera® Antimicrobial Wound Dressing is the only wound dressing in the world powered by Advanced Microcurrent Technology. It is a new generation solution for wound and incisional care with demonstrated broad-spectrum antimicrobial efficacy3 and the ability to promote wound healing4, and is available exclusively through Arthrex as JumpStart Technology with Advanced Microcurrent Healing.

Procellera / JumpStart is currently used in multiple acute and chronic wound care settings, including clinical, animal and consumer health. The company’s ongoing mission is to develop and deliver evidence-based, patient-focused and cost-effective solutions, backed by a commitment to quality and innovation for the improvement of lives.

About Arthrex
Arthrex, Inc. is a global medical device company and leader in new product development and medical education in orthopaedics. With a corporate mission of helping surgeons treat their patients better, Arthrex has pioneered the field of arthroscopy and developed more than 8,500 innovative products and surgical procedures to advance minimally invasive orthopaedics worldwide. Arthrex remains dedicated to delivering uncompromising quality to the healthcare professionals who use its products, and ultimately, the millions of patients whose lives these products impact.

  1. Kim H, Izadjoo MJ. Antibiofilm efficacy evaluation of a bioelectric dressing in mono- and multi-species biofilms. J Wound Care 2015; 24 Suppl 2:S10-4.
  2. Banerjee J, Ghatak PD, Roy S, Khanna S, Hemann C, Deng B, et al. (2015) Silver-Zinc Redox-Coupled Electroceutical Wound Dressing Disrupts Bacterial Biofilm. PLoS ONE 10(3): e0119531. doi:10.1371/journal.pone.0119531
  3. Kim H, Makin I, Skiba J, Ho A, Housler G, Stojadinovic A, Izadjoo M. Antibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens.  The Open Microbiology Journal 2014; 8:15-21.
  4. Banerjee J, Ghatak P, Roy S, Khanna S, Sequin EK, Bellman K, Dickinson BC, Suri P, Subramaniam V, Chang CJ, Sen CK.  Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLOS ONE. 2014; 9(3).
Health Care

Frost & Sullivan Uncovers How Healthcare Providers Can Achieve Better and More Cost-Effective Care Using IT Solutions

admin

— The healthcare industry can offer efficient customer care and communication through the use of cloud-based data storage solutions.

MOUNTAIN VIEW, Calif., March 31, 2015 /PRNewswire/ — The Affordable Care Act along with the intense pressure to reduce healthcare costs has affected the state of the healthcare system, leaving an open door of opportunity for the IT Industry. Healthcare reform is driving a shift towards Accountable Care Organizations (ACOs), wherein the industry will adopt an outcome-based versus procedure-based focus and reimbursement model.

ACOs are investing in products and technologies to meet the healthcare industry’s needs through various kinds of partnerships. There are substantial opportunities in mHealth, as patients increasingly use mobile apps to access and send information on their health, make appointments, and communicate with their healthcare provider, as well as track their wellness and fitness.

New analysis from Frost & Sullivan, The Future of IT in the Healthcare Industry in North America, Latin America, and Europe, finds that integrated delivery network (IDN) providers must continue to invest in IT solutions and infrastructure to meet the needs of delivery practices and information utilization.

For complimentary access to more information on this research, please visit: http://bit.ly/1CCMg2t

“By providing use cases and demonstrating ROI, the IT industry can expand the scaled use of mobile and remote technology solutions as part of care delivery and patient/provider workflows,” said Frost & Sullivan Customer Research Director Tonya Fowler. “IT solutions can have a huge impact on the bottom line by enabling shared information across an organization.”

The traditional paradigm of patient-centric care is gradually giving way to member engagement and empowerment, which in turn, has opened up opportunities for healthcare providers in the untapped health and wellness sector. Many competitors have already begun to lay the ground work with investments in staff, resources, and targeted acquisitions.

Meanwhile, device manufacturers seek to retain clients with cutting-edge customer care technologies that generate timely and effective results. The big data trend is pivotal and numerous IT vendors have responded by developing cloud-based solutions for the healthcare industry.

The amount of big data needed to provide better and more cost-effective care is best handled in the cloud. The capacity, flexibility, and pricing models presented by cloud service providers resonate well with the healthcare industry.

“Furthermore, the adoption of Health Insurance Portability and Accountability Act (HIPAA)-compliant cloud solutions for data storage and archiving is expanding. Applications in the cloud that support collaboration as well as anytime, anywhere, and any-device needs are growing quickly,” noted Fowler. “Niche healthcare cloud service providers will emerge as top contenders in the market, followed by cloud computing vendors that design solutions for healthcare.”

The Future of IT in the Healthcare Industry in North America, Latin America, and Europe is part of the Vertical Markets in ICT (http://www.ict.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Big Data Study 2014, Healthcare IT Trends in Brazil, Top 10 ICT Trends for Africa in 2015, 2014 Latin America Cloud Computing Market, and Profiling the Back Office Workforce Optimization Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

The Future of IT in the Healthcare Industry in North America, Latin America, and Europe
NEA0-67

Contact: 
Clarissa Castaneda 
Corporate Communications – North America 
P: +1.210.477.8481 
F: +1.210.348.1003 
E: clarissa.castaneda@frost.com

http://www.frost.com

Health Care

Senegal, The Philippines, and Uruguay Make Major Strides Towards Universal Access to Reproductive Health

admin

— Global Leaders Council for Reproductive Health honors innovative leadership

WASHINGTON, March 30, 2015 /PRNewswire/ — The Global Leaders Council for Reproductive Health and the Aspen Institute announced today the winners of the 2015 Resolve Award, which recognizes countries that are making landmark progress towards the goal of universal access to reproductive health. This year’s awards are focused on approaches that are anchored in rights-based principles and promote equitable access. Senegal and the Philippines are being honored for exceptional achievements in service delivery and policy development, with special mention to Uruguay for its pioneering approach to risk reduction.

http://reproductivehealth.aspeninstitute.org/

Delivering on the promise of universal access to reproductive health is one of the key human rights challenges facing governments today, and is central to developing a just, equitable, and sustainable world.

The Honorable Joy Phumaphi, Chair of the Aspen Institute’s Global Leaders Council for Reproductive Health, will present the awards to representatives of each country on May 21, 2015, at a ceremony coinciding with the World Health Assembly in Geneva, Switzerland.

Winning Countries
Senegal is the winner of the 2015 Resolve Award for Service Delivery. The country is revolutionizing the availability and supply of contraceptives with its Informed Push Model of distribution. Informed Push uses techniques borrowed from the commercial sector to eliminate inventory stockouts and ensure that women have access to a consistent, reliable supply of family planning products. Development of the system was led by the Ministry of Health, which collaborated with a range of public and private partners to build a robust, sustainable program. The success in Senegal has been dramatic—with stockout frequencies reduced from 80 percent to less than 10 percent—and is already serving as a model for other countries in the region.

The 2015 Resolve Award for Policy Development recognizes the Philippines for its game-changing transformations in the political and regulatory environment for reproductive health. The country’s newly enacted reproductive health law is the result of a 13-year campaign to establish a national reproductive rights and health framework, despite a difficult political climate. The successful culmination of this effort, which was supported by a broad consortium of civil society advocates and government leaders, heralds a new era in health and rights for all Filipinos.

Uruguay is being honored with a Special Mention for its innovative risk reduction approach to unsafe abortion. The Uruguayan model is designed to maximize women’s healthcare options even in a restrictive legal environment, with a focus on treating abortion and unwanted pregnancy as medical issues. As a result, maternal deaths from unsafe abortion have been virtually eliminated in Uruguay. This risk reduction model has been replicated in other countries across Latin America, and is now being implemented in Africa and the Arab world.

About the Awards
The Resolve Award was launched in 2011 by the Global Leaders Council for Reproductive Health, in partnership with Aspen Global Health and Development, the World Health Organization Department of Reproductive Health and Research, and the U.S. Agency for International Development, to recognize country-led innovations that result in increased access to family planning and reproductive health. Past recipients include Ethiopia, Malawi, Nepal, and Yemen (2012); the Gambia, Kenya, Sierra Leone, and Zambia (2013); and Afghanistan, Cambodia, Peru, and Tanzania (2014).

The awards ceremony will be broadcast live on May 21, 2015. Additional information will follow. Join the conversation on Twitter @GLCRHresolve and #Resolve.

The Global Leaders Council for Reproductive Health, established by The Aspen Institute in 2010, is composed of sixteen sitting and former heads of state, high-level policymakers and other leaders who build political leadership for increased financial and technical support for reproductive health. The Council works to revitalize political commitments to reproductive health by increasing awareness of reproductive health issues, supporting the effective use of donor resources, and championing policies dedicated to achieving universal access to reproductive health. For more information please visit: http://reproductivehealth.aspeninstitute.org/

Aspen Global Health and Development, one of the largest policy programs at the Aspen Institute, is a force for fresh thinking, unlikely collaborations, and nimble action within the global health and development field. Today, GHD’s small, dynamic team works on a collection of issue-specific initiatives – all aimed at catalyzing policy work that better connects champions at the highest levels, development practitioners in the field, and the poorest and most vulnerable on the ground. For more information please visit: http://www.aspeninstitute.org/policy-work/global-health-development

Logo –

http://photos.prnewswire.com/prnh/20150329/195106LOGO

Health Care

Automated Endoscope Reprocessors: Procedure Volumes and Replacement Demand Drive Market in Europe

admin

– Strong competition in the replacement segment calls for product innovation and new strategies, finds Frost & Sullivan

LONDON, March 24, 2015 /PRNewswire/ — For a decade now, the volume of endoscopic procedures in Western Europe has been rising steadily. This has increased the demand for automated endoscope reprocessors (AERs), which facilitate high-level disinfection of endoscopes. Endoscopy units and small clinics have been installing AERs to maintain throughput, enhance efficiency, and avoid the transportation delays arising from reprocessing in a central sterile supply department.

Frost & Sullivan

Frost & Sullivan

Logo – http://photos.prnewswire.com/prnh/20150324/184016LOGO

New analysis from Frost & Sullivan, Automated Endoscope Reprocessor Market Trends in Western Europe, finds that the market earned revenues of $133.3 million in 2014 and estimates this to reach $154.6 million in 2019. The study covers pass through and single door AERs.

For complimentary access to more information on this research, please visit: http://corpcom.frost.com/forms/EU_PR_AZanchi_M98C-54_24Mar15

Currently, the replacement of existing AERs, along with a limited number of new installations, is driving sales in Western Europe. With the improvement in AER technology, however, the replacement market, which has been primarily responsible for revenue growth, is witnessing competition that is redefining the products used in the region.

“Having undergone a sea change due to technological developments, the Western European AER market is seeing reduced brand loyalty, which is affecting players’ share of the installed base,” said Frost & Sullivan Healthcare Research Manager Sowmya Rajagopalan. “To retain and gain market share in this replacement-driven market, AER original equipment manufacturers (OEMs) need to invest their time and resources in product innovation.”

Although market share dynamics might continue to change, demand for AERs is unlikely to be hampered as expenditure to control hospital-acquired infections is rising drastically in Western Europe. Despite the market nearing saturation, the uptake of AER remains promising due to the increase in clinics and endoscopy units in hospitals.

The market has not reached its true potential as AERs are used for a longer period than the prescribed product lifecycle. Faced with the residual effects of the economic downturn, end users have shown a tendency to use old AERs rather than invest in new, costly products.

“On the upside, with the move to conduct endoscopic procedures outside the hospital setting, new business opportunities and changing demand patterns from the clinical community are emerging,” noted Rajagopalan. “As a result, AER OEMs are altering their marketing strategies and product positioning to suit these trends. Going forward, partnerships between endoscope manufacturers and AER suppliers could become a market standard to sell into hospitals.”

Automated Endoscope Reprocessor Market Trends in Western Europe is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: Western and Eastern European Custom Procedure Trays and Packs (CPTP) Market, Western European Percutaneous Coronary Intervention (PCI) Devices Market, Western European Infant Care Solutions Market, and Global Orthopaedic Implant Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20150324/8521501872

Health Care

Australia’s Healthcare Has Good Vital Signs, But Sustainability, Costs And Sources Of Funding Are Critical Areas, Says Frost & Sullivan

admin

– Onus to shift to consumers for healthcare spending as an aging population, chronic diseases and healthcare expenses grow

SYDNEY, March 24, 2015 /PRNewswire/ — In 2013, Australia’s healthcare per capita hit A$6,200 per annum, making up 9.3% of GDP. This ranks the highest in the Asia Pacific region in terms of expenditure per capita; and second highest as a percentage of GDP; exceeded slightly only by Japan. From 2013 to 2020, Australia’s spending is expected to increase at a CAGR of 3.2% from A$190 billion in 2013 to A$238 billion in 2020, accounting for nearly 10% of GDP then.

Rhenu Bhuller, Partner and Senior Vice President, Healthcare Asia Pacific, Frost & Sullivan

Rhenu Bhuller, Partner and Senior Vice President, Healthcare Asia Pacific, Frost & Sullivan

In 2013, Australia’s public expenditure was 68% after Japan in first place at 83% and Thailand second at 76%. Healthcare expenditure broken down by sector was 38% in hospitals, 36% in primary care, 20% in capital expenditure and 6% in other recurrent areas. Primary healthcare expenditure increased 61.8% in the last 10 years.

“Naturally with these statistics, sustainability of current levels of expenditure, cost management, and sources of funding are essential factors that need addressing. Privatization of government health service and government funded R&D will be strong focus areas,” said Rhenu Bhuller, Partner and Senior Vice President, Healthcare, Frost & Sullivan Asia Pacific.

“While Government spending will focus on development of public healthcare infrastructure, adoption and implementation of technology and chronic and infectious diseases control and treatment, private healthcare spending is expected to see consistent growth to 2020 with out-of-pocket spending expected to rise at more than 8% each year,” said Bhuller.

State and territory government funding for hospitals have increased by 78.6% over the last 10 years while non-government expenditure on hospitals increased by 88.6%. In 2013, Australia had 1,355 hospitals, and this is expected to grow largely through more public-private partnerships; such as the Bendigo Hospital and HP with the Royal Adelaide Hospital.

68% of healthcare funding was by the government, whilst the 32% of non government spending was contributed to by 26.3% out-of-pocket, 11.8% private insurance and 8.5% others. Over 2012 and 2013, out-of-pocket spending in Australia grew 8.2% and non-government spending increased 10%. Year-on-year growth in both these areas was more than government spending, indicating the increasing contribution from individuals in healthcare payments.

An aging population and rising incidence of chronic conditions like cardiovascular and pulmonary diseases are forcing the government and healthcare providers to take a two pronged approach towards improving health quality and reducing cost of care through exploring chronic disease management programs that help patients stay out of the hospital; and adopting Population Health Management programs that reduce disease cost and risk over a sizeable population. “Moving healthcare delivery from hospitals to primary and community care is a prerogative for the government. Various public and private providers are exploring technology-based solutions to improve efficiency of healthcare services, as well as drive changes in consumer behavior towards preventive healthcare,” Bhuller said. Aged care products and services in areas like home healthcare and remote patient monitoring will be crucial to support independent aging and aging in place. 

The key trends for healthcare in Australia will be that increasingly, consumers will be given responsibility for health, complementary therapies will gain recognition, competition in aged care will intensify, integrated platforms will be a necessity for chronic disease management and a rise of GP super clinics will be inevitable to reduce the load on hospitals.

Complimentary Medicine (CM) includes a wide set of specialty, herbal, and natural or medicines that are regulated under the Therapeutic Goods Act 1989 and typically includes vitamins and minerals, nutritional supplements, homeopathic medicines and Chinese medicines. Scientific literature documenting the medical and cost benefits of complementary therapies is mounting and spreading awareness around wellness and healthy behaviors has the potential to yield billions in net economic benefit. Clinicians as well as regulators will encourage the use of complementary therapies in healthcare, mainly as a step towards prevention and healthy living.

Australia’s population of over 65 will almost double over the next three decades and government spending on aged care is expected to rise by almost 7% year-on-year. Frost & Sullivan expects increased M&As in this area with the sector witnessing an influx of non-traditional players. “Beyond government paid customers, aged care service providers will target the high-end segment with more sophisticated offerings; such as resort-style facilities and in-home health monitoring,” said Bhuller.

An increase in chronic diseases means a social and economic burden as more people live with a compromised quality of life, and the cost of care will rise and burden healthcare services. Mobile health platforms will emerge as a vital aspect of chronic disease management and consumers will increasing need to invest in home monitoring devices and use apps and emergency response systems. Practitioners and insurers will promote mHealth platforms for chronic disease management that integrate various mobile devices, patient monitoring technologies and apps.

The Government has allocated almost A$570 million towards establishing 60 GP Super Clinics and expanding 425 existing GP, primary care and community health services. These government sponsored GP Super Clinics providers comprise integrated practices that house practice nurses, AHPs, visiting medical specialists and other healthcare providers to provide primary care services. GP Super Clinics and other models of remote care delivery, such as telehealth at pharmacies and primary care service providers are intended to help move healthcare outside the hospital, a move that Frost & Sullivan believes is crucial to manage long term healthcare costs.

Frost & Sullivan’s 2015 Healthcare outlook comprises global, APAC, individual country and Health IT sections. The full briefing was presented in Sydney on March 19, 2015.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion

Media Contact:

Donna Jeremiah
Corporate Communications — Asia Pacific
P: +612–82478927
F: +612-92528066
E: djeremiah@frost.com

http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20150324/8521501869

Health Care PUB

How to Build a Solid Healthcare Content Management Foundation for Data Ownership, Interoperability and a Complete Patient Record

admin

— Frost & Sullivan white paper reveals an approach centered on three qualities essential to optimal healthcare performance and value-based care delivery

MOUNTAIN VIEW, Calif., March 23, 2015 /PRNewswire/ — There is a growing perception by healthcare providers that their recent investments in electronic medical record (EMR) and IT infrastructure systems have failed to fully meet the strategic objectives of the enterprise. As healthcare delivery organizations try to move past this state of dissatisfaction and on to developing an action plan, the solution becomes clear. A more effective management of data generated throughout the organization is one of the cornerstones of a modernization effort. In addition, this resolves many pressing challenges on clinical and business efficiencies.

Frost & Sullivan

Frost & Sullivan

Logo – http://photos.prnewswire.com/prnh/20150320/183539LOGO

Frost & Sullivan’s recently published white paper, entitled Directions in Healthcare Content Management: Building a Solid Foundation for Data Ownership, Interoperability and a Complete Patient Record, discloses the implementation of EMR systems and the inability to rely on them exclusively.  

Click HERE to download the white paper, or visit: http://bit.ly/1wDNVnq

As EMRs continue to monopolize IT spending and resources, the challenge of “Big Data” is growing in scope and urgency, along with pressure from other demands, including meaningful use and ICD-9 to ICD-10 transition deadlines. The concept of a comprehensive content platform to optimize the EMR has been gaining ground in the healthcare market. This strategy emphasizes the need to provide a more solid data management foundation underlying the EMR.

“Providers wanting to realize the full potential of EMR investments are looking to augment EMR capabilities to deliver more useful and relevant patient data in a timely manner to each consumer of those data throughout the enterprise – that is, to achieve true data liquidity,” said Frost & Sullivan Imaging Informatics Industry Principal, Nadim Daher.

In this analysis, Frost & Sullivan explains how enhanced information management and information-sharing are critical components of revamping any healthcare content management strategy needed to succeed with the mission.

Lexmark Healthcare is a technology leader with a rich history of providing innovative solutions for managing unstructured content across the healthcare continuum. Lexmark Healthcare supports a modular approach to securely capture, manage, view and share documents, medical images and patient-related information with core healthcare applications.

“Healthcare providers seeking to join or start a healthcare information exchange (HIE) or population health management system, need to make it as cost-efficient as possible in the absence of a clear business and sustainability model,” said Daher.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. 

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.

Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?  

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing” 

Register:        Gain access to visionary innovation

Media Contact:

Kayla Belcher                                                      
Corporate Communications – North America
P: +1 210.247.2450
F: +1 210.348.1003
kayla.belcher@frost.com 
http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20150321/8521501811

Fashion

Nuvesse Skin Therapies Announces Presentation of Top-line Clinical Data Supporting Ability of Cellulation™ Technology to Actively Deliver Topically Applied Skin Therapies Faster and Deeper

admin

— Data Presented at 73rd Annual American Academy of Dermatology Annual Meeting

CASTRO VALLEY, Calif., March 23, 2015 /PRNewswire/ — Nuvesse Skin Therapies, a leading cosmetic skin care company, today announced the presentation of positive data demonstrating the ability of the company’s CellulationTM Technology to actively deliver topically applied skin therapies into the epidermis. This patented serum technology calms, cools and hydrates after aesthetic medical skin treatments. Nuvesse has incorporated this applied science into an expanded portfolio of products designed to facilitate the passage of beneficial skin care constituents across the tough stratum corneum skin barrier into the epidermis, the source of many skin care concerns.

The data, presented at the 73rd Annual American Academy of Dermatology (AAD) Annual Meeting, are believed to be the first findings demonstrating the ability to deliver large molecules directly into the epidermis intact, without damage to the outermost layer of the skin. Complete data from the trials have been accepted for upcoming publication in a peer-reviewed medical journal.

“The most significant challenge in skin rejuvenation has been to penetrate the stratum corneum and deliver beneficial constituents deeper within the skin where they are most needed. These clinical findings demonstrate the ability of CellulationTM Technology to enhance treatment benefits and aid in the corrective process,” said Philip Werschler, M.D., associate clinical professor of medicine/dermatology, University of Washington, and medical director of Nuvesse. “It’s extremely notable that the majority of investigators and patients alike agreed that NuvesseMD products enhanced procedure outcomes, were well-tolerated, easy to use and they would elect to use such products in the future.”

Findings presented included topline results from an in-vitro study, demonstrating the proprietary biochemical product formulation and transport delivery by CellulationTM technology, and a multi-center, proof-of-concept IRB approved clinical study evaluating NuvesseMD facial masks in four different treatment protocols in a total of 140 patients. (Translational Technology for Non-Disruptive Stratum Corneum High Molecular Weight Carrier Assist, AAD Poster #1399).

The first clinical protocol evaluated the safety and efficacy of a Nuvesse Serum No. 3 Post Treatment mask used as an adjunctive agent following ablative or fractional ablative laser resurfacing. In this protocol, 100 percent of investigators agreed that patients were healing more quickly than compared to standard post-treatment protocol. Ninety-one percent of physicians agreed they would use the product again, and all agreed that patients were satisfied with the experience of using the mask.

The other three protocols involved the use of a Nuvesse Serum No. 5 Hydrating mask as an adjunctive agent in microdermabrasion and a Serum No. 25 Lip and Serum No. 21 Crow’s Feet Mask as an adjuvant agent for cosmetic facial procedures. In the microdermabrasion protocol, 91 percent of investigators agreed that patients’ erythema resolved more quickly than without use of the mask, and 51 percent of investigators agreed that patient’s fine lines and wrinkles appeared to have improved after just one wearing. Nearly all (97 percent) of investigators reported they would use the product again. In the Lip and Crow’s Feet protocols, 60 percent of investigators agreed or strongly agreed that patients’ fine lines and wrinkles appeared to have improved after only one treatment and 94 percent reported they would use the product again.

“The ability to deliver treatments past the outer layer of the skin deep within the epidermis represents a new generation of skin technology. This technology has applicability both as a stand-alone treatment and to improve existing skin care treatment modalities and topical applications,” said Dennis Condon, chief executive officer and co-founder of Nuvesse. “The potential of Cellulation Technology and Nuvesse products in skin care is vast, and we look forward to the continued expansion and introduction of this approach, which has the potential to significantly impact and improve the future of skin care for people worldwide.”

About CellulationTM Technology

Cellulation Technology is derived from a wound care application designed to penetrate the stratum corneum in a revolutionary way – transporting large molecules across the outer skin barrier to penetrate into the epidermis. Standard skin care treatments (ablative and non-ablative) primarily involve a healing response and are associated with side effects including swelling and edema. Cellulation Technology, applied in a topical mask or roller application, can deliver molecules through the stratum corneum without injury and is designed to aid in significant skin enhancement.

About Nuvesse Skin Therapies

Nuvesse is a leading cosmetic skin therapy company focused on the advancement of a CellulationTM Technology. The company’s skin therapy serums evolved out of a history of clinically validated wound healing science. It includes science-based serums and infused into biocellulose masks and roller applicators which effectively address skin care concerns such as post-treatment skin, fine lines, and wrinkles. For more information, visit www.nuvessemd.com.

Media Contact:
Julie Garlikov
info@nuvesse.com
+1-510-876-8152

Health Care

Convenience and Cost Savings Bolster Adoption Rates of Patient Portals in Africa

admin

– Technology explosion facilitates the rollout of patient portal services, finds Frost & Sullivan

CAPE TOWN, South Africa, March 18, 2015 /PRNewswire/ — Healthcare givers in Africa are gradually recognising the convenience and cost benefits of adopting patient portals that integrate financial and clinical data. This service not only improves anytime, easy, and secure access to patient data, but also reduces the cost of care and helps eliminate penalties such as readmissions.

New analysis from Frost & Sullivan, Patient Portals in Africa (https://www.frost.com/q293854655), finds that while healthcare providers and payers in Africa clearly understand the value of patient portals, they do not perceive any urgent need to implement them. However, advantages such as patient engagement will encourage uptake in the future.

If you are interested in more information on this study, please send an e-mail to Samantha James, Corporate Communications, at samantha.james@frost.com.

As the patient portal market in Africa is nascent, it is marked by challenges relating to costs and data security. Among end users, insurance payers were the first to adopt similar eHealth technologies, which were mainly used to make patient records available to doctors. The installed base of these technologies has the potential to be upgraded to patient portals, once end users are made aware of its multiple benefits.

“The ability of patient portals’ to optimise the operational and financial efficiency of healthcare providers and payers by leveraging time-saving technologies is a key purchasing factor,” said Frost & Sullivan Healthcare Research Analyst Saravanan Thangaraj. “Further, it can ease some of the tedious and monotonous administrative, as well as data-entry, tasks that consume hospital resources. Patient portals also eliminate the need for additional staff and postage by enabling patients to perform functions online.”

Currently, substitute technologies such as mobile applications (mHealth) and telemedicine have outstripped patient portals in popularity, but this situation may change in due course. Mobile applications may soon be overshadowed by applications that employ both mobile and web-based portals, as they enhance user engagement by allowing customers to choose the technology they wish to adopt.

“The ubiquity of technology has stoked the use of online services and therefore, has fostered an environment that is ideal for the promotion of patient portals,” observed Thangaraj.

Patient portals facilitate real-time health monitoring and patient engagement, which will ultimately lead to patient retention. They also make it possible to interact with patients who relocate, or patients living in rural areas who have difficulties visiting physicians and doctors.

Apart from the obvious cost and convenience benefits, partnerships between payers and designated service providers to have a common patient portal will greatly enrich patient engagement and encourage its uptake.

Patient Portals in Africa is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. This Market Insight looks at the overall patient portal market in Africa with a detailed analysis of the South African and Kenyan markets. It provides the major drivers and restraints for market growth. In addition, the advantages of adopting patient portals are highlighted along with the industry trends. The different types of patient portals, the elements impacting their growth, and a brief customer analysis are also included.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Patient Portals in Africa
9AB9

Contact:
Samantha James
Corporate Communications – Africa
P: +27-21-680-3574
F: +27-21-680-3296
E: samantha.james@frost.com

http://www.frost.com